Table 4. Connectivity Scores and Permutation BH-values of Novel Predicted Type I, II, and III Perturbagens.
Perturbagen | Cancer | Male Score | Female Score | Predicted Type | BH-value |
---|---|---|---|---|---|
CDK1 knockdown | LIHC | 74.26 | −66.44 | I | <0.0001 |
PTPN1 knockdown | LUSC | 70.89 | −86.40 | I | <0.0001 |
SMAD3 knockdown | HNSC | −79.27 | 82.37 | II | <0.0001 |
HSPA4 knockdown | HNSC | −80.84 | 78.58 | II | <0.0001 |
Midostaurin | All | −71.30 | 89.33 | II | <0.0001 |
Etoposide | LIHC | 98.76 | 99.70 | III | 0.9575 |
Camptothecin | LIHC | 98.97 | 99.25 | III | 0.9498 |
The table summarizes several predictions for sex-dependent and sex-independent perturbagens. The BH-value quantifies the statistical significance of the male-female connectivity score difference, as computed by our permutation analyses (see Materials and Methods). “All” indicates that the perturbagen prediction was made on pan-cancer resistance and sensitivity signatures.